Shawn Flanagan

515 total citations
19 papers, 426 citations indexed

About

Shawn Flanagan is a scholar working on Infectious Diseases, Pharmacology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Shawn Flanagan has authored 19 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 6 papers in Pharmacology and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Shawn Flanagan's work include Antimicrobial Resistance in Staphylococcus (6 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Antifungal resistance and susceptibility (4 papers). Shawn Flanagan is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (6 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Antifungal resistance and susceptibility (4 papers). Shawn Flanagan collaborates with scholars based in United States, Netherlands and Israel. Shawn Flanagan's co-authors include Philippe Prokocimer, Edward Fang, William J. Kraemer, Sonia L. Minassian, Craig R. Denegar, Kenneth Mace, Leigh MacConell, Michaëla Diamant, Voon Ong and Kristin Taylor and has published in prestigious journals such as Journal of Applied Physiology, Antimicrobial Agents and Chemotherapy and Critical Care Medicine.

In The Last Decade

Shawn Flanagan

18 papers receiving 408 citations

Peers

Countries citing papers authored by Shawn Flanagan

Since Specialization

Citations

This map shows the geographic impact of Shawn Flanagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shawn Flanagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shawn Flanagan more than expected).

Fields of papers citing papers by Shawn Flanagan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shawn Flanagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shawn Flanagan. The network helps show where Shawn Flanagan may publish in the future.

Co-authorship network of co-authors of Shawn Flanagan

This figure shows the co-authorship network connecting the top 25 collaborators of Shawn Flanagan. A scholar is included among the top collaborators of Shawn Flanagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shawn Flanagan. Shawn Flanagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	573. CD388, a Novel Drug-Fc Conjugate (DFC), Demonstrates Prophylactic Activity in an Influenza Human Challenge Model 2025 ·Open Forum Infectious Diseases ·Ozlem Equils, Shawn Flanagan, (unknown), Johan Vingerhoets, Wilbert van Duijnhoven, Alex Mann, Roxana E. Rojas, Taylor Sandison	0
2	A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects 2022 ·Clinical and Translational Science ·(unknown), Dennis Ruff, (unknown), (unknown), (unknown), Taylor Sandison, Shawn Flanagan	3
3	637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin 2020 ·Open Forum Infectious Diseases ·José A. Vázquez, Shawn Flanagan, Peter G. Pappas, George R. Thompson, Taylor Sandison, Patrick M. Honoré	3
4	679: Effect of Moderate Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin 2020 ·Critical Care Medicine ·Voon Ong, Taylor Sandison, (unknown), Thomas Marbury, (unknown), Alena Jandourek, Shawn Flanagan	1
5	CD101 Prophylactic Dose Rationale for Prevention of Aspergillus, Candida, and Pneumocystis Infections 2018 ·Biology of Blood and Marrow Transplantation ·Shawn Flanagan, Taylor Sandison, Jeffrey B. Locke, Voon Ong, Guofeng Ye, Ken Bartizal, (unknown)	6
6	Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid Phosphate 2018 ·Antimicrobial Agents and Chemotherapy ·Jianying Xiao, Charles Gill, Lianzhu Liang, Jenny Liu, Jin Wu, Hwa-ping Feng, Shawn Flanagan, Christopher M. Tan, Amy Flattery	7
7	Determination of Tedizolid susceptibility interpretive criteria for gram-positive pathogens according to clinical and laboratory standards institute guidelines 2017 ·Diagnostic Microbiology and Infectious Disease ·Mekki Bensaci, Shawn Flanagan, Taylor Sandison	3
8	Bioactive growth hormone in older men and women: It's relationship to immune markers and healthspan 2017 ·Growth Hormone & IGF Research ·William J. Kraemer, Mary J. Kennett, Andrea M. Mastro, Roger McCarter, Connie J. Rogers, William H. DuPont, Shawn Flanagan, William J. Turbitt, Maren S. Fragala, (unknown), Wesley C. Hymer	7
9	Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects 2017 ·The Journal of Clinical Pharmacology ·Shawn Flanagan, Sonia L. Minassian, Julie Passarell, Jill Fiedler‐Kelly, Philippe Prokocimer	11
10	Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents 2016 ·The Pediatric Infectious Disease Journal ·John S. Bradley, Shawn Flanagan, Antonio Arrieta, Richard F. Jacobs, Edmund V. Capparelli, Philippe Prokocimer	20
11	Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration 2015 ·Drugs in R&D ·Gerard A. Kennedy, (unknown), Shawn Flanagan, (unknown), (unknown)	6
12	The influence of age and exercise modality on growth hormone bioactivity in women 2014 ·Growth Hormone & IGF Research ·Scott E. Gordon, William J. Kraemer, David P. Looney, Shawn Flanagan, Brett A. Comstock, Wesley C. Hymer	12
13	Absorption, Distribution, Metabolism, and Excretion of the Novel Antibacterial Prodrug Tedizolid Phosphate 2014 ·Drug Metabolism and Disposition ·Voon Ong, Shawn Flanagan, Edward Fang, (unknown), Jeffrey B. Locke, Kenneth F. Bartizal, Philippe Prokocimer	62
14	Single‐ and Multiple‐Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid 2014 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Shawn Flanagan, Edward Fang, (unknown), Sonia L. Minassian, Philippe Prokocimer	75
15	Resistance exercise induces region-specific adaptations in anterior pituitary gland structure and function in rats 2013 ·Journal of Applied Physiology ·William J. Kraemer, Shawn Flanagan, Jeff S. Volek, Bradley C. Nindl, Jakob L. Vingren, Courtenay Dunn‐Lewis, Brett A. Comstock, David R. Hooper, Tunde K. Szivak, David P. Looney, Carl M. Maresh, Wesley C. Hymer	20
16	EEG Measures of Cortical Activity with Different Types of Acute Resistance Exercise Workouts 2011 ·The Journal of Strength and Conditioning Research ·Brett A. Comstock, Shawn Flanagan, Courtenay Dunn‐Lewis, Jeff S. Volek, William J. Kraemer, Nicholas M. Kelly, Brent C. Creighton	2
17	Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing 2010 ·Clinical Pharmacokinetics ·Mark Fineman, Shawn Flanagan, Kristin Taylor, (unknown), Larry Z. Shen, Kenneth Mace, Brandon Walsh, Michaëla Diamant, Brenda Cirincione, Prajakti A. Kothare, (unknown), Leigh MacConell	117
18	Recovery From Injury in Sport: Considerations in the Transition From Medical Care to Performance Care 2009 ·Sports Health A Multidisciplinary Approach ·William J. Kraemer, Craig R. Denegar, Shawn Flanagan	37
19	Contributions of Saturable Active Secretion, Passive Transcellular, and Paracellular Diffusion to the Overall Transport of Furosemide Across Adenocarcinoma (Caco-2) Cells 2002 ·Journal of Pharmaceutical Sciences ·Shawn Flanagan, (unknown), Xiaoli Liu, Leslie Z. Benet	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact